Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study-Reference-Cited by-同舟云学术

Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study

Published:2012-10 Issue:4 Volume:76 Page:756-760
ISSN:0016-5107
Container-title:Gastrointestinal Endoscopy
language:en
Short-container-title:Gastrointestinal Endoscopy

Author:

Lee Yin-Mei,Low How Cheng,Lim Lee Guan,Dan Yock Young,Aung Myat Oo,Cheng Chee Leong,Wee Aileen,Lim Seng Gee,Ho Khek Yu

Publisher

Elsevier BV

Subject

Gastroenterology,Radiology, Nuclear Medicine and imaging

Reference12 articles.

1. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines;Chitturi;J Gastroenterol Hepatol,2007

2. Nonalcoholic fatty liver disease: an agenda for clinical research;Younossi;Hepatology,2002

3. Therapeutic effects of restricted exercise in obese patients with fatty liver;Ueno;J Hepatol,1997

4. Liver involvement in obese children;Franzese;Dig Dis Sci,1997

5. Hepatic effects of dietary weight loss in morbidly obese subjects;Andersen;J Hepatol,1991

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis;Clinical and Molecular Hepatology;2024-07-01

2. Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease;World Journal of Gastroenterology;2024-06-21

3. How to incorporate endohepatology into your bariatric practice;iGIE;2024-06

4. Evaluating Weight Loss Efficacy in Obesity Treatment with Allurion’s Ingestible Gastric Balloon: A Retrospective Study Utilizing the Scale App Health Tracker;Clinics and Practice;2024-05-06

5. Endo-bariatric therapies as a treatment strategy for MASLD;Clinical Liver Disease;2024-01